Catamaran Prior Authorization Department. Phone: Fax: Prescriber Information. Member Information.
|
|
- Dortha Houston
- 6 years ago
- Views:
Transcription
1 Prescriber Information Last Name First Name DEA / NPI Specialty Phone Member Information Last Name Fax First Name Member ID Number DOB Medication Information: Drug Name and Strength: Quantity: Diagnosis: Dosing: SPORANOX CAPSULES, SPORANOX ORAL SOLUTION, ONMEL, JUBLIA, KERYDIN, CICLOPIROX KIT, CICLODAN SOL KIT, CNL8 NAIL KIT and PEDIPIROX-4 NAIL KIT Prior Authorization Sporanox Capsules Page 1 of 6
2 1. Will the patient be receiving concurrent therapy with any of the following drugs metabolized by CYP3A4? Methadone Disopyramide Dofetilide Dronedarone Quinidine ergot alkaloids lovastatin simvastatin irinotecan lurasidone oral midazolam pimozide triazolam felodipine nisoldipine ranolazine eplerenone cisapride ticagrelor fesoterodine* telithromycin* solifenacin* colchicine* 2. Does the patient have one of the following diagnoses? (If yes, please circle below.) A) Systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis) B) Tinea corporis (ringworm) C) Tinea cruris (jock itch) D) Tinea pedis (athlete s foot) E) Tinea capitis (scalp ringworm) F) Pityriasis versicolor G) Onychomycosis Tinea Infection Section 3. Is the patient s condition resistant to topical antifungal therapy? Onychomycosis Section 4. Has the diagnosis of onychomycosis been confirmed by one of the following? A. Positive potassium hydroxide (KOH) preparation B. Culture C. Histology Page 2 of 6
3 5. Does the patient have one of the following contraindications or exclusions to the use of itraconazole? (If yes, please circle below.) A. Ventricular dysfunction B. Congestive heart failure (CHF) C. History of CHF D. Pregnancy or intent to become pregnant 6. Is the patient s condition causing debility or a disruption in their activities of daily living? 7. Did the patient try and have an inadequate response, intolerance, or hypersensitivity to oral terbinafine therapy? 8. Is the onychomycosis affecting the patient s fingernails, toenails, or both? (Please circle below.) A) Fingernails B) Toenails C) Both (fingernails and toenails) Sporanox Oral Solution 1. Will the patient be receiving concurrent therapy with any of the following drugs metabolized by CYP3A4? Methadone Disopyramide Dofetilide Dronedarone Quinidine ergot alkaloids lovastatin simvastatin irinotecan lurasidone oral midazolam pimozide triazolam felodipine nisoldipine ranolazine eplerenone cisapride ticagrelor fesoterodine* telithromycin* solifenacin* Page 3 of 6
4 2. Does the patient have one of the following diagnoses? (If yes, please circle below.) A) Systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis) B) Tinea corporis (ringworm) C) Tinea cruris (jock itch) D) Tinea pedis (athlete s foot) E) Tinea capitis (scalp ringworm) F) Pityriasis versicolor G) Candidiasis (esophageal or oropharyngeal) Tinea Infection Section 3. Is the patient s condition resistant to topical antifungal therapy? Candidiasis (Esophageal or Oropharyngeal) Section 4. Is the candidiasis (esophageal or oropharyngeal) refractory to treatment with fluconazole? Onmel 1. Does the patient have one of the following contraindications or exclusions to the use of itraconazole? (If yes, please circle below.) A. Ventricular dysfunction B. Congestive heart failure (CHF) C. History of CHF D. Pregnancy or intent to become pregnant E. Receiving concurrent therapy with any of the following drugs metabolized by CYP3A4? Cisapride Pimozide Quinidine Dofetilide Levacetylmethadol Felodipine Oral midazolam Nisoldipine Triazolam Lovastatin Simvastatin Ergot alkaloids Methadone 2. Does the patient have a diagnosis of onychomycosis? 3. Has the diagnosis of onychomycosis been confirmed by one of the following? A. Positive potassium hydroxide (KOH) preparation B. Culture C. Histology Page 4 of 6
5 4. Is the patient s condition causing debility or a disruption in their activities of daily living? 5. Did the patient try and have an inadequate response, intolerance, or hypersensitivity to oral terbinafine therapy? 6. Is the onychomycosis affecting the patient s fingernails, toenails, or both? (Please circle below.) A) Fingernails B) Toenails C) Both (fingernails and toenails) Jublia 1. Does the patient have a diagnosis of onychomycosis of the toenails confirmed by one of the following? A) Positive potassium hydroxide (KOH) preparation B) Culture C) Histology 2. Does the patient have dermatophytomas or lunula (matrix) involvement? 3. Does the patient have mild to moderate disease defined by the presence of all of the following? A) Involvement of at least 1 great toenail B) The target great toenail (TGT) includes at least a 3 mm section of clear nail (measured from the proximal nail fold) and less than or equal to a 3 mm distal toenail plate thickness C) 20% to 50% clinical involvement of the target toenail 4. Has the patient had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine? 5. Is the patient s condition causing debility or a disruption in their activities of daily living? Kerydin 1. Does the patient have a diagnosis of onychomycosis of the toenails confirmed by one of the following? A) Positive potassium hydroxide (KOH) preparation B) Culture C) Histology 2. Does the patient have dermatophytomas or lunula (matrix) involvement? 3. Does the patient have mild to moderate disease defined by the presence of all of the following? A) Involvement of at least 1 great toenail B) The target great toenail (TGT) includes at least a 3 mm section of clear nail (measured from the proximal nail fold) and less than or equal to a 3 mm distal toenail plate thickness C) 20% to 60% clinical involvement of the target toenail Page 5 of 6
6 4. Has the patient had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine? 5. Is the patient s condition causing debility or a disruption in their activities of daily living? Ciclopirox Kit/CNL8 Nail Kit/Pedipirox-4 Nail Kit 1. Does the patient have a diagnosis of onychomycosis of the toenails and/or fingernails that has been confirmed by one of the following? A) Positive potassium hydroxide (KOH) preparation B) Culture C) Histology 2. Does the patient have dermatophytomas or lunula (matrix) involvement? 3. Does the patient have mild to moderate disease defined by the presence of all of the following? A) Involvement of at least 1 great toenail B) The target great toenail (TGT) includes at least a 3 mm section of clear nail (measured from the proximal nail fold) and less than or equal to a 3 mm distal toenail plate thickness C) 20% to 60% clinical involvement of the target toenail 4. Has the patient had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine? 5. Is the patient s condition causing debility or a disruption in their activities of daily living? Comments: Information given on this form is accurate as of this date. Prescriber or Authorized Signature Date Authorized Medical Staff Name/Title Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department at I understand that Catamaran s use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996). Page 6 of 6
Clinical Policy: Itraconazole (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date:
Clinical Policy: (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date: 06.01.15 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Onmel, Sporanox) Reference Number: CP.CPA.134 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other EFINACONAZOLE JUBLIA 41184 TAVABOROLE KERYDIN 41353 GUIDELINES FOR USE 1. Does the patient have a diagnosis of onychomycosis of the fingernail or toenail? If yes,
More informationItraconazole DIGICON. Composition: MOLECULAR INTRODUCTION
Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:
More informationLUZU (luliconazole) external cream
LUZU (luliconazole) external cream Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPharmacy Newsletter. September 17, Q4.
Pharmacy Newsletter September 17, 2014 - Q4 Table of Contents SECTION 1: CMO Message...3 SECTION 2: Medicare Part D Cost Share Reminder...3 SECTION 3: Formulary Changes...4 SECTION 4: FDA Alerts New FDA
More informationItraconazole Capsules
Itraconazole Capsules Rx only BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the November 21, 2013 meeting of the Pharmacy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: itraconazole (Sporanox) Reference Number: HIM.PA.36 Effective Date: 05/16 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important
More information(itraconazole) Oral Solution BOXED WARNING
SPORANOX (itraconazole) Oral Solution BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions: If signs or symptoms of congestive heart failure occur during administration of SPORANOX
More informationPRODUCT MONOGRAPH. itraconazole capsules. 100 mg. Antifungal Agent. Date of Preparation: June 19, 2002
PRODUCT MONOGRAPH Pr SPORANOX itraconazole capsules 100 mg Antifungal Agent Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Preparation: June 19, 2002 Date of Revision:
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET ITRAZOLE 1. Product Name Itrazole 100 mg capsules 2. Qualitative and Quantitative Composition Each capsule contains 100 mg of itraconazole. For the full list of excipients, see section
More informationITRANOX. Composition Each capsule contains :
ITRANOX Composition Each capsule contains : Itraconazole 100 mg Capsules Action Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial
More informationManagement of fungal infection
Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general
More informationSPORANOX Capsules Itraconazole
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationPRODUCT MONOGRAPH. itraconazole capsules. 100 mg. Antifungal Agent
PRODUCT MONOGRAPH Pr MINT-ITRACONAZOLE itraconazole capsules 100 mg Antifungal Agent Mint Pharmaceuticals Inc. 1093 Meyerside Drive, Unit #1 Mississauga, Ontario L5T 1J6 Date of Revision: March 21, 2018
More informationCASE STUDY ADULT CASES OF ONYCHOMYCOSIS. Warren S. Joseph, DPM, FIDSA
ADULT CASES OF ONYCHOMYCOSIS Warren S. Joseph, DPM, FIDSA BACKGROUND (CASE 1) A 41-year-old woman presented with no complaints of pain, but she was concerned about discoloration of her toenails. She has
More informationITRALASE Capsules (Itraconazole)
Published on: 20 Dec 2017 ITRALASE Capsules (Itraconazole) Black Box Warning Congestive Heart Failure, Cardiac Effects and Drug Interactions Itraconazole capsules should not be administered for the treatment
More informationREGIONAL ADMINISTRATIVE INFORMATION. 3. Pharmaceutical form Capsule, hard Elongated, red opaque hard gelatine capsule (size 0)
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationREGIONAL ADMINISTRATIVE INFORMATION
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationSPORANOX Capsules Janssen
SPORANOX Capsules Janssen NAME OF THE MEDICINAL PRODUCT SPORANOX CAPSULES QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100 mg itraconazole in a pellet formulation. PHARMACEUTICAL FORM
More informationAbstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis.
Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN-- Multicentre, double blind parallel group study. SETTING--32
More informationSPORANOX (itraconazole) Oral Solution BOXED WARNING
SPORANOX (itraconazole) Oral Solution BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions: If signs or symptoms of congestive heart failure occur during administration of SPORANOX
More informationMerz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction
PRESS RELEASE Merz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction Greensboro, N.C. (BUSINESS WIRE) Merz North America (Merz Aesthetics,
More informationAbbreviated Class Update: Topical Antifungal Agents. Month/Year of Review: September 2014 Date of Last Review: March 2014
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Itrakonazol Actavis 100 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, hard contains 100 mg of itraconazole.
More informationTINEA (FUNGAL) INFECTION
1 Medical Topics - Tinea TINEA (FUNGAL) INFECTION Tinea infection There are 3 main groups of fungal organisms that can cause skin infections. They include dermatophytes, yeast and moulds. Dermatophytes
More informationKetoconazole pills for toenail fungus
Ketoconazole pills for toenail fungus The Borg System is 100 % Ketoconazole pills for toenail fungus Uses. See also Warning section. Ketoconazole is used to treat certain serious fungal infections in the
More informationPatient Assistance Program
Patient Assistance Program Application INDICATION 1 VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets are indicated for the treatment of adult patients with chronic
More informationSAMPLE IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI:
Please Note: Medical Necessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATION
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationClassification. Distal & Lateral Subungual OM. White Superficial OM. Proximal Subungual OM. Candidal OM. Total dystrophic OM
Onychomycosis Commonest dermatological condition Definition: Infection of the nail caused by fungi that include dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida). 80% of all OM affects
More informationSPORANOX Capsules Itraconazole Consumer Medicine Information
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationBefore you take Itrazole
NEW ZEALAND CONSUMER MEDICINE INFORMATION ITRAZOLE Itraconazole capsule 100 mg What is in this leaflet This leaflet answers some common questions about It does not contain all the available information.
More informationFungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection
Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Faculty Raza Aly, PhD, MPH Professor Emeritus University of California Medical Center (MSSF) Professor, Dermatology Faculty
More informationPRESS RELEASE. Merz North America Announces Change In U.S. Aesthetics (Merz Aesthetics, Inc.) Leadership
PRESS RELEASE Merz North America Announces Change In U.S. Aesthetics (Merz Aesthetics, Inc.) Leadership Greensboro, N.C. (BUSINESS WIRE) Merz North America today announced that Jim Hartman has been appointed
More informationCommon Superficial Fungal Infections
How to recognise and treat Common Superficial Fungal Infections Dr Lilianne Scholtz (MBBCh) Types of superficial fungal infections Ringworm (Tinea) Candida (Thrush) Body Groin Feet Skin Nappy rash Vagina
More informationPRODUCT INFORMATION ITRANOX capsules
PRODUCT INFORMATION ITRANOX capsules NAME OF THE MEDICINE Itraconazole CAS-84625-61-6 C 35 H 38 CI 2 N 8 O 4 MW: 705.64 (+)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-
More informationSporanox 100 mg capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 100 mg capsules Itraconazole Sporanox is a registered trademark Read all of this leaflet carefully before you start taking this medicine because it contains
More informationThe US Onychomycosis Market (2017 Edition) July 2017
The US Onychomycosis Market (2017 Edition) July 2017 The US Onychomycosis Market Report Scope of the Report The report entitled The US Onychomycosis Market (2017 Edition), provides analysis of the US onychomycosis
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Oral solution 10 mg /ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY PROFILE Based on EU SmPC sections
More informationPRODUCT INFORMATION APO-Itraconazole capsules
PRODUCT INFORMATION APO-Itraconazole capsules NAME OF THE MEDICINE Itraconazole CAS-84625-61-6 C35H38CI2N8O4 MW: 705.64 (+)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-
More informationSPORANOX. itraconazole NEW ZEALAND DATA SHEET
SPORANOX itraconazole NEW ZEALAND DATA SHEET 1. PRODUCT NAME SPORANOX itraconazole 10 mg/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml SPORANOX Oral Solution contains 10 mg itraconazole.
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Brian Couse, M.D. Professional Staff: Mark Graber, M.D., FACEP,
More informationSPORANOX Oral Solution Itraconazole
SPORANOX Oral Solution Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX Oral Solution. It does not contain all the available
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationMERCY RETREAT Dermatology
MERCY RETREAT 2016 Dermatology INFECTIONS IN DERMATOLOGY Why we do talk about infections today? These are some of the most commonly seen dermatologic diseases that present to primary care physician office
More informationPRODUCT MONOGRAPH. itraconazole. oral solution 10 mg/ml. Antifungal Agent. Date of Preparation: June 6, 2002
PRODUCT MONOGRAPH Pr SPORANOX itraconazole oral solution 10 mg/ml Antifungal Agent Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Preparation: June 6, 2002 Date
More informationFlukonazol 50mg Capsules, 150mg Capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER Flukonazol 50mg Capsules, 150mg Capsules FLUCONAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY
More informationDISTAL LATERAL SUBUNGUAL ONYCHOMYCOSIS
Boni E. Elewski, MD James Elder Professor of Dermatology University of Alabama RESEARCH GRANTS -TO UNIVERSITY Dusa, Meiji, Valeant, Viamet Amgen, Abbvie, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis,
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationClinical Practice Guideline Superficial Fungal Infection
Clinical Practice Guideline Superficial Fungal Infection ก ก ก กก ก ก ก ก กก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก * ก Superficial fungal infection ก 1. ก (Pityriasis versicolor, Tinea versicolor) 2. ก ก
More informationAll three dermatophytes contain virulence factors that allow them to invade the skin, hair, and nails. Keratinases. Elastase.
DERMATOPHYTOSIS (=Tinea = Ringworm) Infection of the skin, hair or nails caused by a group of keratinophilic fungi, called dermatophytes Microsporum Epidermophyton Hair, skin Skin, nail Tih Trichophyton
More informationSPORANOX Capsules Itraconazole Consumer Medicine Information
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationTinea: Head to Toe A dermatophyte tour of human skin. Tour de Tinea Head to Toe. Tips for Tinea Head to Toe. Psoriasis. Non-inflammatory Tinea Capitis
Tinea: Head to Toe A dermatophyte tour of human skin Renee Howard, MD Assistant Clinical Professor of Dermatology, UCSF Tour de Tinea Head to Toe Tips for Tinea Head to Toe Capitis Faciei Corporis Pedis
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
Dear Patient! You have been prescribed Terbinafine "Genericon" 250 mg - tablets by your doctor, who, in the interests of improving your state of health, considers this product to be suitable for the treatment
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description
CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin
More information2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N
Prior Authorization MERC CARE PLA Weight Reduction Medications (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationMedical Directive. Medical Director: Date Revised: January 23, Executive Director: Date Revised: January 23, 2019
Medical Directive Assessment and Treatment of Onychomycosis and Tinea Pedis Assigned Number: 026 Activation Date: January 1, 2019 Review due by: December 1, 2020 Approval Signature & Date Medical Director:
More informationPRODUCT MONOGRAPH. itraconazole. oral solution 10 mg/ml. Antifungal Agent. Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9
PRODUCT MONOGRAPH Pr SPORANOX itraconazole oral solution 10 mg/ml Antifungal Agent Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Date of Revision: November 24, 2017 www.janssen.com/canada Submission
More informationSPORANOX. itraconazole NEW ZEALAND DATA SHEET
SPORANOX itraconazole NEW ZEALAND DATA SHEET 1. PRODUCT NAME SPORANOX itraconazole 10 mg/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml SPORANOX Oral Solution contains 10 mg itraconazole.
More informationTypes of Skin Infections
Anatomy of Skin Types of Skin Infections Bacterial Impetigo Folliculitis Acne Fungal /Parasitic Tinea Pedis Tinea Cruris Tinea Versicolor Tinea Corporis Toenail fungus Allergic/Irritation conditions Dermatitis
More informationJanssen NAME OF THE MEDICINAL PRODUCT
NIZORAL Tablets Janssen NAME OF THE MEDICINAL PRODUCT NIZORAL Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg ketoconazole. For excipients, see List of Excipients PHARMACEUTICAL
More informationBuckeye Health Plan Medicaid Criteria Updates Q3 2017
Effective date: 07/10/17 Buckeye Health Plan Medicaid Criteria Updates Q3 2017 B uckeye Health Plan (BHP) routinely reviews their Prior Authorization (PA) and Medical Necessity (MN) criteria. Decisions
More informationRead all of this leaflet carefully before you start taking your medicine:
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 10mg/ml Oral Solution (itraconazole) Read all of this leaflet carefully before you start taking your medicine: Keep this leaflet. You may need to read
More informationSPORANOX Oral Solution Itraconazole Consumer Medicine Information
SPORANOX Oral Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information. It does not take the
More informationSAJA PHARMA. Itraconazole 1. NAME OF THE MEDICINAL PRODUCT
08-15 ITRAZOL 100 mg Capsules SAJA PHARMA Itraconazole 1. NAME OF THE MEDICINAL PRODUCT ITRAZOL 100 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ITRAZOL in pink and blue capsules coded by SJ153,
More informationA COMPARATIVE STUDY OF EFFICACY OF TERBINAFINE AND FLUCONAZOLE IN PATIENTS OF TINEA CORPORIS
Int. J. Pharm. Med. & Bio. Sc. 2013 Kumar Amit et al., 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved A COMPARATIVE STUDY OF EFFICACY OF
More informationDiagnosis and Treatment of Infectious, Inflammatory and Neoplastic Nail Conditions
OFFICE DERMATOLOGY, PART I 0025-7125/98 $8.00 +.OO NAIL DISORDERS Diagnosis and Treatment of Infectious, Inflammatory and Neoplastic Nail Conditions Phoebe Rich, MD Nail problems (Table 1) are common complaints
More informationAPO-ITRACONAZOLE Itraconazole capsules
APO- Itraconazole capsules Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 WHAT IS IN THIS LEAFLET This leaflet answers some common questions about APO-. It does not
More informationNizoral 200 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Nizoral 200 mg tablets Ketoconazole Nizoral is a registered trademark Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationSPIMACO. Fluconazole Antifungal Flocazole 150 mg hard capsules. - Mucosal thrush - infection affecting the lining of the. mouth, throat.
08-15 Flocazole SPIMACO Fluconazole Antifungal Flocazole 50 mg hard capsules Flocazole 150 mg hard capsules Flocazole 200 mg hard capsules Fluconazole 1. WHAT FLOCAZOLE IS AND WHAT IT IS USED FOR Flocazole
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 8 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Fluconazole 50 mg Tablets * Fluconazole Read all of this leaflet carefully before you start taking this medicine.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Diflucan 50 mg hard capsules Diflucan 200 mg hard capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER Diflucan 50 mg hard capsules Diflucan 200 mg hard capsules fluconazole Read all of this leaflet carefully before you start taking this medicine - Keep this leaflet.
More informationMolina Healthcare of Texas
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Ingrezza (Marketplace) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information,
More informationBefore you take ITRACAP. When you must not take it
ITRACAP Itraconazole CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about ITRACAP Itraconazole capsules. It does not contain all the available information.
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationClinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice
Clinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice Phoebe Rich, MD; Tracey C. Vlahovic, DPM; Warren S. Joseph, DPM; Lee T. Zane, MD; Steve B.
More informationAntifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals
OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH ILLIOIS (MEDICAID) CS Stimulants (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Somatostatin Analogs (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationPART III: CONSUMER INFORMATION
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr SPORANOX itraconazole capsules This leaflet is Part III of a three-part Product Monograph published when SPORANOX capsules were approved for sale
More informationPRIOR AUTHORIZATION BYPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs
Please ote: Medical ecessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATIO
More information2. Does the patient have a diagnosis of Crohn s disease? Y N
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Stelara (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationFungal nail infection: diagnosis and management
Follow the link from the online version of this article to obtain certified continuing medical education credits Fungal nail infection: diagnosis and management Samantha Eisman, Rodney Sinclair Sinclair
More informationThree clinical cases. fungal infections
Three clinical cases Diagnostic and treatment challenges in skin and mucosal fungal infections Else Svejgaard, MD, Merete Hædersdal, MD Dept. of Dermatology, Bispebjerg University Hospital, Copenhagen,
More informationPackage leaflet: Information for the user. Fluconazole 150 mg hard capsule. Fluconazole 200 mg hard capsule (Fluconazole)
Package leaflet: Information for the user Fluconazole 50 mg hard capsule Fluconazole 150 mg hard capsule Fluconazole 200 mg hard capsule (Fluconazole) Read all of this leaflet carefully before you start
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMycology. BioV 400. Clinical classification. Clinical classification. Fungi as Infectious Agents. Thermal dimorphism. Handout 6
BioV 400 Mycology Handout 6 Fungi as Infectious Agents True or primary fungal pathogens invades and grows in a healthy, noncompromise d host Most striking adaptation to survival and growth in the human
More information3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationCCDS 09/2010 Page 1 of 19
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) SPORANOX 10 mg/ml Oral solution. COMPOSITION Each millilitre oral solution contains 10 mg of itraconazole. Sporanox Oral solution
More information3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationScabies. Scabies 10/22/2012. What s Bugging You? Common Cutaneous Infections and Infestations in Kids
What s Bugging You? Common Cutaneous Infections and Infestations in Kids Andrea L. Zaenglein, MD Associate Professor of Dermatology and Pediatrics Penn State/ Hershey Medical Center Touching the Future
More informationCircle Yes or No Y N. [If yes, skip to question 29.] 2. Is the request for Sandostatin LAR? Y N. [If no, skip to question 5.] Prior Authorization
04/03/2016 Prior Authorization MERC MARICOPA ITEGRATED CARE - TXIX/XXI SMI (MEDICAID) Somatostatin Analogs and Somavert (AZ88) This fax machine is located in a secure location as required by HIPAA regulations.
More informationmiconazole and zinc oxide topical
miconazole and zinc oxide topical Pronunciation: mye KON a zole and ZINK OX ide TOP ik al Brand: Rash Relief Antifungal, Vusion What is the most important information I should know about miconazole and
More information